OncoMatch/Clinical Trials/NCT06437977
Neoadjuvant Therapy of SBRT Sequencial with Toripalimab and Chemotherapy in Resectable Stage II-III NSCLC Patients(neoR-TORCH)
Is NCT06437977 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies Toripalimab for stage ii-iii non-small cell lung cancer.
Treatment: Toripalimab — This is a randomized, controlled, multi-center, phase III clinical study to evaluate the efficacy and safety of SBRT sequencial with Toripalimab and chemotherapy versus Toripalimab and chemotherapy for subjects with resectable, stage II-III NSCLC.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: ALK wild-type
Required: PD-L1 (CD274) any tested (testing required; no eligibility threshold specified)
Required: EGFR wild-type
Disease stage
Required: Stage II, IIIA, IIIB (N2) (AJCC version 8)
Excluded: Stage IIIC
resectable, stage II, IIIA, IIIB (N2) (AJCC staging system, version 8) NSCLC
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: systemic antitumor therapy
Previous treatment with systemic antitumor therapy for early NSCLC, including investigational product
Cannot have received: anti-PD-1/PD-L1 or other targeted T cell receptor therapy
Previous use of PD-1/PD-L1 agent or the drug acting on another targeted T cell receptor (e.g., CTLA-4, OX-40)
Lab requirements
Blood counts
absolute neutrophil count ≥ 1.5 × 109/l, platelet count ≥ 80 × 109/l, hemoglobin ≥9 g/dl
Kidney function
serum creatinine ≤ 1.5 × uln or serum creatinine clearance rate ≥ 60 ml/min; blood urea nitrogen ≤ 200mg/l
Liver function
total bilirubin ≤ 1.5 × uln, alt and ast ≤ 1.5 × uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06437977 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
Does this trial require CD274?
Yes, CD274 any tested is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage II or IIIA or IIIB (N2) is required.
Is there an age limit?
Yes. Patients must be 75 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify